80.
Incyte to buy Star Therapeutics' subsidiary Vega for $1.25B upfront to get a Phase 3 treatment candidate for the …
Incyte to buy Star Therapeutics' subsidiary Vega for $1.25B upfront to get a Phase 3 treatment candidate for the blood disorder von Willebrand disease